MJ AMHTS with Health3nsurance.com share the nutrition knowledge with the presentation from Taipei Medicine University Professor of Nutritional science Hsieh MJ
MJ AMHTS with Health3nsurance.com share the nutrition knowledge with the presentation from Taipei Medicine University Professor of Nutritional science Hsieh MJ
1. Rheumatoid arthritis (RA) is an autoimmune disease where the immune system mistakenly attacks the body's own tissues, causing inflammation in the joints.
2. If left uncontrolled, long-term inflammation from RA can cause joint deformity, disability, and loss of function.
3. RA occurs when cytokines that regulate inflammation become imbalanced, leading to excess production of pro-inflammatory cytokines like interleukin-6, interleukin-1, and tumor necrosis factor-alpha.
New ulmonary arterial hypertension in rheumatic diseases 财团法人风湿病基金会台湾抗风湿病联盟
?
This document summarizes a presentation on pulmonary artery hypertension (PAH) in rheumatic diseases. It begins with a case presentation of a patient diagnosed with limited systemic sclerosis and PAH who was treated with various medications. It then provides background on PAH classification and the pathophysiology of PAH in connective tissue diseases. Specifically, it discusses the prevalence of PAH in different rheumatic diseases like systemic sclerosis, the mechanisms involved in pathogenesis, and differences in phenotypes between SSc-PAH and non-SSc PAH. Treatment approaches are also summarized.
Current diagnosis and management of PAH from cardiologist point of view财团法人风湿病基金会台湾抗风湿病联盟
?
1. Pulmonary arterial hypertension (PAH) is often misdiagnosed or diagnosed late due to non-specific symptoms. Right heart catheterization is the gold standard diagnostic test.
2. PAH can be classified into 5 groups, with Group 1 including idiopathic PAH and PAH associated with conditions like connective tissue diseases.
3. PAH progresses from a reversible stage of endothelial dysfunction and vasoconstriction to an irreversible stage involving structural changes to the pulmonary vasculature. This leads to increased pulmonary vascular resistance and pressures over time.
This document discusses pulmonary hypertension (PH) in patients with connective tissue diseases (CTD). It finds that treatment is less effective for CTD-associated PH (CTD-PAH) compared to idiopathic PAH, with less improvement in walking distance and higher rates of clinical worsening. Combination therapy may be more effective than monotherapy for CTD-PAH. The prognosis of CTD-PAH patients is better if they are short-term responders to treatment or were initially treated with glucocorticoids and immunosuppressants upon PAH and CTD diagnosis. However, treatment outcomes are worse if CTD-PAH patients also have interstitial lung disease. Right ventricular size measured